Taiwan Extracorporeal Co2 Removal Device Market Size & Outlook, 2026-2034
Taiwan Extracorporeal Co2 Removal Device Market Insights
- Based on Reed Intelligence findings, the Taiwan Extracorporeal Co2 Removal Device Market reached USD 1.71 Million in 2025 and is estimated to attain USD 5.18 Million by 2034.
- From 2026 to 2034, the Taiwan market is expected to grow at a steady CAGR of 12.94%.
- Within the Type category, Veno-Venous ECCO2R dominated in 2025 in terms of market size contribution.
- Over the forecast period, Veno-Venous ECCO2R is forecasted to deliver the fastest growth, positioning it as the most lucrative Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Taiwan contributed 1.18% to the global Extracorporeal Co2 Removal Device Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Extracorporeal Co2 Removal Device Market.
- In Asia Pacific, China is projected to capture the leading share of market size by 2034.
- Among Asia Pacific markets, India is expected to post the fastest growth, reaching USD 24.48 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 1.71 Million |
| Market Size In 2034 | USD 5.18 Million |
| Largest segment | Veno-Venous ECCO2R |
| Units | Revenue in USD Million |
| CAGR | 12.94% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Application |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Extracorporeal Co2 Removal Device Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veno-Venous ECCO2R | XX.x | XX.x | XX.x | 0.87 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Arterio-Venous ECCO2R | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Portable ECCO2R Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Extracorporeal Co2 Removal Device Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Critical Care | XX.x | XX.x | XX.x | 0.83 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Emergency Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Chronic Respiratory Management | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Extracorporeal Co2 Removal Device Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 0.89 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
